Features of Genotyping of Complications of The Metabolic Syndrome at The Preclinical Stage

Abstract

Use of the principles personalized medicine for preventing such widespread conditions as metabol-ic syndrome (MS) representing a complex of pathogenetically interrelated metabolic disorders ab-dominal obesity, hypertension, insulin resistance, dislipidemia, actual, as according a number of large epidemiological studies it with products versus about 20 to 45% of fatal complications. MS, allocation of a separate pathology is of great clinical value, claim about Since, on the one hand, this condition is reversible, that is, with appropriate therapy, it is possible to reduce the se-verity of its main manifestations, on the other hand, the presence of MS acts as the main cause of high cardiometabolic risk, combining the risk cardiovascular diseases and the risk of developing diabetes mellitus (DM) type 2, which are the main causes of increased mortality in industrialized countries. With the development of MS, there is a 5-fold increase in the risk of type 2 diabetes and a 2-fold increase in the risk of developing cardiovascular diseases over the next 5-10 years. In ad-dition, in patients with MS, the risk of stroke increases by 2-4 times, by 3-4 times myocardial in-farction, the risk of death from these diseases increases by 2 times compared with patients without MS, regardless of the history of cardiovascular events. Based on the monitoring of individuals after genetic testing and a critical analysis of the results of a prospective genetic analysis, information about the possibilities of pre-symptomatic (prognostic) genetic testing becomes more and more practical. The obtained genotyping data allowed to evaluate the effectiveness of preclinical diagnosis and determine the tactics of treating patients. Materials and Methods: Release of DNA for the subsequent genotyping is made of whole blood by sets of «S-Sorb» reagents of the «Sintol» company with use of a sorbent of dioxide of silicon for 135 patients of State-funded health institution "Central City Clinical Hospital" Veliky Novgo-rod, from them 101 patients – with stroke, 34 patients – with a hypertension, obesity, diabetes 2 types. For studying of genetic predisposition to development of complications of a metabolic syndrome the complex of genetic polymorphisms is allocated. Genotyping on the following genes was carried out: Blood pressure regulation system Thr174Met (rs4762) polymorphism of the angiotensinogen gene (AGT); Hemostasis system polymorphism G-455A (rs1800790) of the fibrinogen gene (FGB); The system of regulation of the inflammatory process polymorphism C174G (rs1800795) of the gene for interleukin-6 (IL6). Single nucleotide genetic polymorphisms of the studied genes were revealed using the “real-time” polymerase chain reaction using «Sintol» reagent kits with specific oligonucleotide primers and TaqMan probes.